Method for in-vitro expansion of CD8<+>T cells

• Main Authors: LIU GUANGPING, WU XIAOXING, YANG JUN
• Format: Patent
• Language: Chinese; English
• Published: 29.06.2016
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; VINEGAR; WINE

The invention provides a method for in-vitro expansion of CD8<+>T cells. The method comprises steps as follows: TIL (tumor infiltrating lymphocyte) cells are extracted from a malignant pleural and peritoneal effusion source, cytokines IL-2, CD3McAb and PD-1 monoclonal antibodies are added to a TIL cell culture medium, the concentration of the IL-2 is 300-1,000 U/ml, the concentration of the CD3McAb is 10-50 ng/ml, and the concentration of the PD-1 monoclonal antibodies is 50-200 ng/ml. The cell factor combination adopted by the method can increase the TIL cell expansion multiple, effectively inhibit the negative regulation effect of Treg cells on the CD8<+>T cells and promote the anti-tumor effect. 本发明提供一种体外扩增CD8T细胞的方法，包括从癌性胸腹水来源提取得到TIL细胞，向TIL细胞培养液中添加细胞因子IL?2、CD3McAb和抗PD?1单克隆抗体，所述的IL?2浓度为300?1000U/ml，CD3McAb浓度为10?50ng/ml，抗PD?1单克隆抗体50?200ng/ml。该方法采用的细胞因子组合能够提高TIL细胞扩增倍数，有效抑制Treg细胞对CD8+T细胞的负向调节作用，促进抗肿瘤效应。